

Aaron C Logan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2959732/publications.pdf>

Version: 2024-02-01

66
papers

2,839
citations

236833

25
h-index

182361

51
g-index

67
all docs

67
docs citations

67
times ranked

4138
citing authors

#	ARTICLE	IF	CITATIONS
1	KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. <i>Lancet</i> , The, 2021, 398, 491-502.	6.3	315
2	Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2019, 9, 1050-1063.	7.7	288
3	Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications. <i>Annals of Internal Medicine</i> , 2011, 154, 529.	2.0	242
4	High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 21194-21199.	3.3	160
5	Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1307-1313.	2.0	124
6	Off-Label Use of Recombinant Factor VIIa in U.S. Hospitals: Analysis of Hospital Records. <i>Annals of Internal Medicine</i> , 2011, 154, 516.	2.0	123
7	Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. <i>Leukemia</i> , 2013, 27, 1659-1665.	3.3	123
8	Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 4407-4417.	0.6	118
9	Factors Influencing the Titer and Infectivity of Lentiviral Vectors. <i>Human Gene Therapy</i> , 2004, 15, 976-988.	1.4	102
10	Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. <i>American Journal of Hematology</i> , 2019, 94, 257-265.	2.0	99
11	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , 2021, 138, 11-22.	0.6	90
12	Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. <i>Current Opinion in Biotechnology</i> , 2002, 13, 429-436.	3.3	81
13	Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E2219-28.	3.3	78
14	Integrated Self-Inactivating Lentiviral Vectors Produce Full-Length Genomic Transcripts Competent for Encapsidation and Integration. <i>Journal of Virology</i> , 2004, 78, 8421-8436.	1.5	76
15	Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. <i>Blood</i> , 2016, 128, 2899-2908.	0.6	70
16	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2002-2007.	2.0	64
17	Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice. <i>Blood</i> , 2019, 133, 2104-2108.	0.6	63
18	The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters. <i>Blood Reviews</i> , 2017, 31, 173-183.	2.8	57

#	ARTICLE	IF	CITATIONS
19	Breakthrough Invasive Fungal Infections on Isavuconazole Prophylaxis and Treatment: What Is Happening in the Real-World Setting?. <i>Clinical Infectious Diseases</i> , 2018, 67, 1142-1143.	2.9	57
20	Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. <i>Blood</i> , 2019, 133, 2069-2078.	0.6	47
21	Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 189-196.	2.0	38
22	Recombinant Factor VIIa: An Assessment of Evidence Regarding Its Efficacy and Safety in the Off-Label Setting. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 153-159.	0.9	37
23	ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 746-754.	2.0	37
24	The Moloney Murine Leukemia Virus Repressor Binding Site Represses Expression in Murine and Human Hematopoietic Stem Cells. <i>Journal of Virology</i> , 2003, 77, 9439-9450.	1.5	36
25	Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1218-1224.	2.0	32
26	The road to purified hematopoietic stem cell transplants is paved with antibodies. <i>Current Opinion in Immunology</i> , 2012, 24, 640-648.	2.4	23
27	Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1974-1982.	2.0	23
28	Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	23
29	Acute Liver Failure Secondary to Hemophagocytic Lymphohistiocytosis during Pregnancy. <i>ACG Case Reports Journal</i> , 2016, 3, e162.	0.2	17
30	Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. <i>British Journal of Haematology</i> , 2022, 197, 63-70.	1.2	16
31	A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. <i>EClinicalMedicine</i> , 2021, 33, 100787.	3.2	14
32	The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 844-854.	1.9	13
33	Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. <i>Bone Marrow Transplantation</i> , 2015, 50, 40-44.	1.3	12
34	Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1030-1036.	2.0	11
35	Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. <i>Leukemia and Lymphoma</i> , 2016, 57, 1560-1566.	0.6	11
36	Using Social Media at National Meetings in Hematology—Optimal Use, Tips, Strategies, and Limitations. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 605-610.	1.2	11

#	ARTICLE	IF	CITATIONS
37	Comprehensive Geriatric Assessment Identifies Significant Functional Impairments in Older Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S65-S66.	2.0	10
38	Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 32-33.	0.6	10
39	Cancer Vaccines and T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S97-S101.	2.0	9
40	Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease. <i>JAMA Dermatology</i> , 2015, 151, 635.	2.0	9
41	The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 132-139.	1.2	8
42	Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	8
43	Inhibition of MET Signaling with Ficlatusumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. <i>Blood Cancer Discovery</i> , 2021, 2, 434-449.	2.6	7
44	Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 897-897.	0.6	7
45	What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 543-543.	0.7	7
46	Serial comprehensive geriatric and quality of life assessments in adults age ≥50 years undergoing autologous hematopoietic cell transplantation. <i>Journal of Geriatric Oncology</i> , 2021, 12, 531-539.	0.5	6
47	Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. <i>European Journal of Haematology</i> , 2021, 107, 343-353.	1.1	5
48	JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID). <i>Blood</i> , 2021, 138, 554-554.	0.6	5
49	Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer. <i>Cancer Investigation</i> , 2012, 30, 231-235.	0.6	3
50	Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008, 49, 581-585.	0.6	2
51	Impaired B Cell Clonotype Diversification After Allogeneic Hematopoietic Cell Transplantation Predicts Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S148-S149.	2.0	2
52	Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S307-S308.	2.0	2
53	A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 377-383.	0.2	2
54	Obinutuzumab-induced serum sickness following salvage therapy for chronic lymphocytic leukemia. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 891-893.	0.2	2

#	ARTICLE	IF	CITATIONS
55	Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 309.e1-309.e9.	0.6	2
56	Accessory splenules in autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2013, 88, 156-156.	2.0	1
57	A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401. <i>Blood</i> , 2018, 132, 4018-4018.	0.6	1
58	Off-Label Use of Recombinant Factor VIIa. <i>Annals of Internal Medicine</i> , 2011, 155, 338.	2.0	0
59	A Phase 1 Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination with Etoposide As Preparative Therapy for Autologous Stem Cell Transplant in Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S114-S115.	2.0	0
60	Long-Term Outcomes of 133 Patients with Intermediate-Risk Acute Myeloid Leukemia Treated with High-Dose Chemotherapy and Autologous Stem Cell Rescue in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S141-S142.	2.0	0
61	Novel Transplant and Post-Transplant Options in ALL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S7-S9.	0.2	0
62	Systemic VEGF Inhibition Induces Hepatic EPO Production and Erythrocytosis Via HIF-2a-Dependent and -Independent Mechanisms. <i>Blood</i> , 2008, 112, 482-482.	0.6	0
63	High-Throughput VDJ Sequencing Is Superior to Quantitative PCR and Flow Cytometry for the Quantification of Minimal Residual Disease In Chronic Lymphocytic Leukemia After Hematopoietic Cell Transplantation.. <i>Blood</i> , 2010, 116, 1290-1290.	0.6	0
64	Panobinostat-Augmented Cytarabine and Daunorubicin (7+3) Induction for Older Patients with AML or High-Risk MDS Is Well Tolerated and Results in Favorable Clinical Outcomes: The Panda Trial. <i>Blood</i> , 2015, 126, 1337-1337.	0.6	0
65	Heterogeneity of Minimal/Measurable Residual Disease (MRD) Practices in Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in the United States. <i>Blood</i> , 2021, 138, 4478-4478.	0.6	0
66	SOHO State of the Art Updates and Next Questions: Novel Transplant and Post-Transplant Options in Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	0